# A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer

> **NCT05145218** · PHASE3 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 405 (estimated)

## Conditions studied

- Recurrent Platinum-resistant Ovarian Cancer

## Interventions

- **DRUG:** Anlotinib Hydrochloride Capsules
- **DRUG:** Paclitaxel injection
- **DRUG:** TQB2450 injection

## Key facts

- **NCT ID:** NCT05145218
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-28
- **Primary completion:** 2024-10
- **Final completion:** 2024-12
- **Target enrollment:** 405 (ESTIMATED)
- **Last updated:** 2021-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05145218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05145218, "A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05145218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*